Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: shasta23 who wrote (11001)	11/12/1997 3:11:00 PM
From: lavalamp	Read Replies (1) \| Respond to of 32384

KINDA off topic Stefan, If you like sarcasm, check out sarcasm.com if you are just in a bad mood you should try clonlara.org be sure and click on all the blue words;) let's pretend we made a significant test of the bottom and are now prepared for a significant price rise:>

To: shasta23 who wrote (11001)	11/12/1997 3:55:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

> And it looks like that LGND has stabilized for now 14 3/8 Back down to todays low of 13 3/4's > Is that because Greenspan didn't hike the rate? Looks like it did not have a positive effect (DOW down 150).

To: shasta23 who wrote (11001)	11/13/1997 6:19:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Stefan , ALRT came out with financials showing about $22 million in the bank at the end of 3Q. Nothing new in the release other than the statement that the Nov 3 call date is dependent on a success registration, which seems to be taking slightly more time than expected.

To: shasta23 who wrote (11001)	11/13/1997 7:56:00 AM
From: Henry Niman	Respond to of 32384

Here's Dow Jones' version of today's press release: Allergan Ligand 3Q Losses $3.22 A Share Vs $2.73 Dow Jones Newswires Allergan Ligand Retinoid Therapeutics Inc. - San Diego 3rd Quar Sept. 30: 1997 1996 Revenues -a $211,000 $926,000 Net income (10,461,000) (8,857,000) Shr earns Net income (3.22) (2.73) 9 Months: Revenues -a 1,323,000 3,014,000 Net income (29,214,000) (20,267,000) Shr earns Net income (8.99) (6.24) Figures in parentheses are losses. a. Interest income. Allergan Ligand Retinoid Therapeutics Inc. was formed in 1994 by Ligand Pharmaceuticals Inc. and Allergan Inc. to accelerate development of retinoid medications being pursued jointly by the companies. Allergan Ligand said a more rapid discovery and development program for a significantly larger library of viable retinoid compounds than anticipated at the time of formation will result in accelerated spending, which could result in the use of substantially all of the funds available for research and development remaining in Allergan Ligand in late 1997 or early 1998. As reported in September, Ligand and Allergan exercised their options to acquire the assets of Allergan Ligand for $21.97 a share, or $71.4 million, and to dissolve the company. Current quote for: ALRI \| AGN \| LGND